Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 10:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 471 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Corneal Diseases Clear all
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections

NCT05750589
View directory record Official record
Conditions
Retinal Disease
Interventions
IRX-101, Providone-Iodine
Drug
Lead sponsor
iRenix Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Jun 26, 2026, 10:50 AM EDT
Recruiting Phase 2 Interventional

DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy

NCT07024693
View directory record Official record
Conditions
Fuchs Endothelial Corneal Dystrophy, Fuchs
Interventions
DT-168
Drug
Lead sponsor
Design Therapeutics, Inc.
Industry
Eligibility
30 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Indianapolis, Indiana • Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 28, 2025 · Synced Jun 26, 2026, 10:50 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Antibiotic Resistance and Microbiome in Children Aged 6-59 Months in Nouna, Burkina Faso

NCT03187834
View directory record Official record
Conditions
Child Development
Interventions
Azithromycin, Amoxicillin, Cotrimoxazole, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
6 Months to 59 Months
Enrollment
252 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Jun 26, 2026, 10:50 AM EDT
Terminated Phase 3 Interventional Results available

Safety Study of the VEGA UV-A System to Treat Keratoconus

NCT01190306
View directory record Official record
Conditions
Keratoconus
Interventions
The VEGA UV-A Illumination System, Riboflavin
Device · Drug
Lead sponsor
Topcon Medical Systems, Inc.
Industry
Eligibility
12 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
9
States / cities
Phoenix, Arizona • Atlanta, Georgia • Bloomington, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Jun 26, 2026, 10:50 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)

NCT02121301
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
Low Dose 0.155µg/mL SkQ1 ophthalmic solution, High Dose 1.55µg/mL SkQ1 ophthalmic solution, Placebo (Vehicle) opthalmic solution
Drug
Lead sponsor
Mitotech, SA
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2020 · Synced Jun 26, 2026, 10:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety & Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution

NCT04667572
View directory record Official record
Conditions
Keratoconus, Pellucid Marginal Corneal Degeneration, Corneal Degeneration, Corneal Ectasia
Interventions
PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
Combination Product
Lead sponsor
Cornea Associates of Texas
Other
Eligibility
8 Years and older
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Jun 26, 2026, 10:50 AM EDT
Recruiting Phase 3 Interventional

Compassionate Use Study of Epi-ON Corneal Collagen Crosslinking Performed Using UVA Exposure on Eyes With Ectatic Corneal Diseases for Subjects With Down Syndrome

NCT07135167
View directory record Official record
Conditions
Down Syndrome (DS), Keratoconus, Pellucid Marginal Degeneration, Forme Fruste Keratoconus (FFK)
Interventions
Epi-ON corneal cross-linking (CXL)
Combination Product
Lead sponsor
Woolfson Eye Institute
Other
Eligibility
8 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
12
States / cities
Atlanta, Georgia • Canton, Georgia • Cumming, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Jun 26, 2026, 10:50 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Corneal Elastography and Patient Specific Modeling

NCT03030755
View directory record Official record
Conditions
Cornea; Ectasia, Refractive Errors, Keratoconus
Interventions
Optical coherence tomography
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
16 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jun 26, 2026, 10:50 AM EDT
Recruiting Phase 1 Interventional

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Corneal Scars

NCT06257355
View directory record Official record
Conditions
Corneal Scar
Interventions
CSB-001 Ophthalmic Solution 0.1%
Biological
Lead sponsor
Claris Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Loma Linda, California • Carmel, Indiana • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Jun 26, 2026, 10:50 AM EDT
Recruiting Phase 1 Interventional

Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking

NCT03918408
View directory record Official record
Conditions
Keratoconus, Unstable, Bacterial Keratitis, Ectasia of Cornea
Interventions
PXL-330 Platinum device for crosslinking with Peschke ribofflavin solution
Combination Product
Lead sponsor
Pacific Clear Vision Institute
Other
Eligibility
12 Years to 45 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Jun 26, 2026, 10:50 AM EDT
Not yet recruiting Phase 2 Interventional

Fluorometholone Study

NCT07308938
View directory record Official record
Conditions
Keratitis Bacterial, Corneal Ulcer (Diagnosis)
Interventions
Adjunctive Topical Fluorometholone (FML) 0.1%, Standard Topical Antibiotic Therapy
Drug
Lead sponsor
Vishal Jhanji
Other
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jun 26, 2026, 10:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ocular Surface Immune Response in Dry Eye Disease

NCT02042820
View directory record Official record
Conditions
Dry Eye Disease
Interventions
In vivo confocal microscopy (IVCM)
Other
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Jun 26, 2026, 10:50 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Corticosteroid Dosing Regimens After Endothelial Keratoplasty

NCT01853696
View directory record Official record
Conditions
Fuchs' Dystrophy, Corneal Edema
Interventions
loteprednol etabonate, prednisolone acetate 1%
Drug
Lead sponsor
Cornea Research Foundation of America
Other
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Jun 26, 2026, 10:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

OCT Agreement and Crossed Precision Study

NCT02050880
View directory record Official record
Conditions
Glaucoma, Retinal Disease, Corneal Disease
Interventions
Not listed
Lead sponsor
Nidek Co. LTD.
Industry
Eligibility
20 Years and older
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2014 · Synced Jun 26, 2026, 10:50 AM EDT
Active, not recruiting Phase 1 Interventional

Stem Cell Therapy for Limbal Stem Cell Deficiency

NCT03957954
View directory record Official record
Conditions
Limbal Stem-cell Deficiency
Interventions
cLSC, Scleral contact lens (SCL)
Biological · Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jun 26, 2026, 10:50 AM EDT
Active, not recruiting Phase 2 Interventional

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

NCT00092222
View directory record Official record
Conditions
Lymphoproliferative Disorder, HHV-8, Malignancy, HIV
Interventions
Etoposide, Interferon-alpha, Rituximab, Zidovudine, Liposomal Doxorubicin, Bortezomib, Valganciclovir, Doxorubicin, Vincristine, Cyclophosphamide, Filgrastim (G-CSF), Prednisone, Sirolimus, Observation Only
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 26, 2026, 10:50 AM EDT
Not listed Phase 3 Interventional

A Clinical Trial to Evaluate a Corneal Inlay for the Improvement of Near and Intermediate Vision in Pseudophakic Presbyopic Subjects

NCT02668523
View directory record Official record
Conditions
Presbyopia, Pseudophakia
Interventions
Raindrop Near Vision Inlay
Device
Lead sponsor
ReVision Optics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
13
States / cities
Laguna Hills, California • Orange, California • Bradenton, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Jun 26, 2026, 10:50 AM EDT
Recruiting Phase 4 Interventional

The Effects of 3% Trehalose Ophthalmic Solution on Corneal Epithelial Barrier Function

NCT06655441
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
3% trehalose
Drug
Lead sponsor
Southern California College of Optometry at Marshall B. Ketchum University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Fullerton, California
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 26, 2026, 10:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)

NCT00851734
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
voclosporin ophthalmic solution
Drug
Lead sponsor
Lux Biosciences, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Conshohocken, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 21, 2012 · Synced Jun 26, 2026, 10:50 AM EDT
Completed Phase 1 Interventional Results available

Topical Avastin for Treatment of Corneal Neovascularization

NCT00559936
View directory record Official record
Conditions
Corneal Neovascularization
Interventions
Topical Avastin 1%
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Jun 26, 2026, 10:50 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Gamma-Irradiated Corneal Inlay for Keratoconus

NCT04895514
View directory record Official record
Conditions
Keratoconus
Interventions
Gamma-irradiated corneal tissue inlay
Procedure
Lead sponsor
Cornea and Laser Eye Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Jun 26, 2026, 10:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease

NCT05586152
View directory record Official record
Conditions
Dry Eye Disease
Interventions
INV-102, Vehicle
Drug
Lead sponsor
Invirsa, Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rush, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jun 26, 2026, 10:50 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease

NCT03933904
View directory record Official record
Conditions
Castleman Disease, Castleman's Disease, Multicentric
Interventions
Sirolimus
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
2 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Little Rock, Arkansas • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Jun 26, 2026, 10:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Post Photorefractive Keratectomy (PRK) Use of an Eye Shield for Maintaining Vision and Mitigating Pain

NCT01592643
View directory record Official record
Conditions
Pain, Vision Nearsighted
Interventions
Eye Shield
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2021 · Synced Jun 26, 2026, 10:50 AM EDT